Increase of Soluble RAGE in Cerebrospinal Fluid following Subarachnoid Haemorrhage

Biomed Res Int. 2017:2017:7931534. doi: 10.1155/2017/7931534. Epub 2017 May 29.

Abstract

Receptors for advanced glycation end-products (RAGE) mediate the inflammatory reaction that follows aneurysmal subarachnoid haemorrhage. Soluble RAGE (sRAGE) may function as a decoy receptor. The significance of this endogenous anti-inflammatory mechanism in subarachnoid haemorrhage (SAH) remains unknown. The present study aims to analyse sRAGE levels in the cerebrospinal fluid (CSF) of SAH patients. sRAGE levels were assayed by ELISA kit in 47 CSF samples collected on post-SAH days 0-3, 5-7, and 10-14 from 27 SAH patients with acute hydrocephalus. CSF levels of sRAGE were compared with a control group and correlated with other monitored parameters. In the control group, the CSF contained only a trace amount of sRAGE. By contrast, the CSF of 20 SAH patients collected on post-SAH days 0-3 was found to contain statistically significant higher levels of sRAGE (mean concentration 3.91 pg/mL, p < 0.001). The most pronounced difference in CSF sRAGE levels between good and poor outcome patients was found on days 0-3 post-SAH but did not reach the significance threshold (p = 0.234). CSF sRAGE levels did not change significantly during hospitalisation (p = 0.868) and correlated poorly with treatment outcome, systemic inflammatory markers, and other monitored parameters. Our study revealed an early and constant increase of sRAGE level in the CSF of SAH patients.

Publication types

  • Clinical Trial
  • Observational Study

MeSH terms

  • Biomarkers / cerebrospinal fluid
  • Enzyme-Linked Immunosorbent Assay / methods
  • Female
  • Humans
  • Intracranial Aneurysm / cerebrospinal fluid*
  • Male
  • Prospective Studies
  • Receptor for Advanced Glycation End Products / metabolism*
  • Subarachnoid Hemorrhage / cerebrospinal fluid*

Substances

  • AGER protein, human
  • Biomarkers
  • Receptor for Advanced Glycation End Products